Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Boosted tipranavir versus darunavir in treatment-experienced patients: observational data from the randomized POTENT trial.

Elgadi MM, Piliero PJ.

Drugs R D. 2011 Dec 1;11(4):295-302. doi: 10.2165/11596340-000000000-00000.

2.

Susceptibility of HIV-1 to tipranavir and other antiretroviral agents in treatment-experienced patients: The UTILIZE Study.

Baxter JD, Bhatti L, Coakley E, Bartczak J, McDonough M, Vinisko R, Piliero PJ.

Curr HIV Res. 2010 Jun;8(4):347-54.

PMID:
20353387
3.

Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone.

Bruce RD, Altice FL, Moody DE, Lin SN, Fang WB, Sabo JP, Wruck JM, Piliero PJ, Conner C, Andrews L, Friedland GH.

Drug Alcohol Depend. 2009 Dec 1;105(3):234-9. doi: 10.1016/j.drugalcdep.2009.07.007. Epub 2009 Sep 1.

4.

Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers.

Pham PA, la Porte CJ, Lee LS, van Heeswijk R, Sabo JP, Elgadi MM, Piliero PJ, Barditch-Crovo P, Fuchs E, Flexner C, Cameron DW.

Antimicrob Agents Chemother. 2009 Oct;53(10):4385-92. doi: 10.1128/AAC.00449-09. Epub 2009 Aug 10.

5.

Pharmacokinetic assessment of nevirapine and metabolites in human immunodeficiency virus type 1-infected patients with hepatic fibrosis.

Cammett AM, MacGregor TR, Wruck JM, Felizarta F, Miailhes P, Mallolas J, Piliero PJ.

Antimicrob Agents Chemother. 2009 Oct;53(10):4147-52. doi: 10.1128/AAC.00460-09. Epub 2009 Jul 20.

6.

Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravir.

Mathias AA, Hinkle J, Shen G, Enejosa J, Piliero PJ, Sekar V, Mack R, Tomaka F, Kearney BP.

J Acquir Immune Defic Syndr. 2008 Oct 1;49(2):156-62. doi: 10.1097/QAI.0b013e318183a982.

PMID:
18769354
7.

Ritonavir-boosted protease inhibitors: impact of ritonavir on toxicities in treatment-experienced patients.

Sension M, Piliero PJ.

J Assoc Nurses AIDS Care. 2007 Jan-Feb;18(1):36-47.

PMID:
17338984
8.

Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjects.

DeJesus E, Piliero PJ, Summers K, Wire MB, Stein DS, Masterman A, Lou Y, Min SS, Shelton MJ.

Antimicrob Agents Chemother. 2006 Sep;50(9):3157-9.

9.

Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials.

Nelson M, Arastéh K, Clotet B, Cooper DA, Henry K, Katlama C, Lalezari JP, Lazzarin A, Montaner JS, O'Hearn M, Piliero PJ, Reynes J, Trottier B, Walmsley SL, Cohen C, Eron JJ Jr, Kuritzkes DR, Lange J, Stellbrink HJ, Delfraissy JF, Buss NE, Donatacci L, Wat C, Smiley L, Wilkinson M, Valentine A, Guimaraes D, Demasi R, Chung J, Salgo MP.

J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):404-12.

PMID:
16280694
10.

Strategies for initiating combination antiretroviral therapy.

Tapper ML, Daar ES, Piliero PJ, Smith K, Steinhart C.

AIDS Patient Care STDS. 2005 Apr;19(4):224-38. Review.

PMID:
15857194
11.

Atazanavir: A novel once-daily protease inhibitor.

Piliero PJ.

Drugs Today (Barc). 2004 Nov;40(11):901-12. Review.

PMID:
15645003
12.

Atazanavir--a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials.

Cahn PE, Gatell JM, Squires K, Percival LD, Piliero PJ, Sanne IA, Shelton S, Lazzarin A, Odeshoo L, Kelleher TD, Thiry A, Giordano MD, Schnittman SM.

J Int Assoc Physicians AIDS Care (Chic). 2004 Jul-Sep;3(3):92-8. Review.

PMID:
15573713
13.

Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors.

Piliero PJ.

J Acquir Immune Defic Syndr. 2004 Sep 1;37 Suppl 1:S2-S12. Review.

PMID:
15319664
14.

An assessment of herbal therapy use, adherence and utilization of pharmacy services in HIV clinics.

Faragon JJ, Purdy BD, Piliero PJ.

J Herb Pharmacother. 2002;2(1):27-37.

PMID:
15277104
15.

Buffalo hump: what the experts suggest.

Piliero PJ, McComsey GA.

AIDS Clin Care. 2004 Mar;16(3):22-3. No abstract available.

PMID:
15119294
16.

Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers.

Wire MB, Ballow C, Preston SL, Hendrix CW, Piliero PJ, Lou Y, Stein DS.

AIDS. 2004 Apr 9;18(6):897-907.

PMID:
15060437
17.

Diaphragmatic paralysis due to isolated phrenic neuropathy in an HIV-infected man.

Piliero PJ, Estanislao L, Simpson D.

Neurology. 2004 Jan 13;62(1):154-5. No abstract available.

PMID:
14718726
18.

Pharmacodynamics and clinical use of anti-HIV drugs.

Preston SL, Piliero PJ, Drusano GL.

Infect Dis Clin North Am. 2003 Sep;17(3):651-74. Review.

PMID:
14711082
19.
20.

Drug interactions associated with HAART: focus on treatments for addiction and recreational drugs.

Faragon JJ, Piliero PJ.

AIDS Read. 2003 Sep;13(9):433-4, 437-41, 446-50. Review.

PMID:
14598790
21.

Use of ultrasonography-assisted liposuction for the treatment of human immunodeficiency virus-associated enlargement of the dorsocervical fat pad.

Piliero PJ, Hubbard M, King J, Faragon JJ.

Clin Infect Dis. 2003 Nov 15;37(10):1374-7. Epub 2003 Oct 13.

PMID:
14583872
22.
23.

Early factors in successful anti-HIV treatment.

Piliero PJ.

J Int Assoc Physicians AIDS Care (Chic). 2003 Jan-Mar;2(1):10-20. Review.

PMID:
12942662
24.

Simplified regimens for treating HIV infection and AIDS.

Piliero PJ, Colagreco JP.

J Am Acad Nurse Pract. 2003 Jul;15(7):305-12. Review.

PMID:
12929251
25.

Editorial comment: fewer prescribing errors in the 21st Century?

Piliero PJ.

AIDS Read. 2003 Jun;13(6):277. No abstract available.

PMID:
12846172
26.

T cells containing T cell receptor excision circles are inversely related to HIV replication and are selectively and rapidly released into circulation with antiretroviral treatment.

Diaz M, Douek DC, Valdez H, Hill BJ, Peterson D, Sanne I, Piliero PJ, Koup RA, Green SB, Schnittman S, Lederman MM.

AIDS. 2003 May 23;17(8):1145-9.

PMID:
12819515
27.

Guillain-Barré syndrome associated with immune reconstitution.

Piliero PJ, Fish DG, Preston S, Cunningham D, Kinchelow T, Salgo M, Qian J, Drusano GL.

Clin Infect Dis. 2003 May 1;36(9):e111-4. Epub 2003 Apr 14.

PMID:
12715328
28.

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.

Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, Walmsley S, Cohen C, Kuritzkes DR, Eron JJ Jr, Chung J, DeMasi R, Donatacci L, Drobnes C, Delehanty J, Salgo M; TORO 1 Study Group.

N Engl J Med. 2003 May 29;348(22):2175-85. Epub 2003 Mar 13. Erratum in: N Engl J Med. 2003 Sep 11;349(11):1100.

29.

Antiretroviral rounds. Failure to achieve full virologic suppression.

Piliero PJ, Jenny-Avital ER.

AIDS Clin Care. 2002 Nov;14(11):100-1. No abstract available.

PMID:
12434768
30.

Case report. Hepatitis B virus and HIV coinfection.

Piliero PJ, Faragon JJ.

AIDS Read. 2002 Oct;12(10):443-4, 448-51.

PMID:
12408101
31.

Atazanavir: a novel HIV-1 protease inhibitor.

Piliero PJ.

Expert Opin Investig Drugs. 2002 Sep;11(9):1295-301. Review.

PMID:
12225250
32.

Antiretroviral rounds. Personal and public consequences.

Sax PE, Piliero PJ.

AIDS Clin Care. 2000 Jan;12(1):4-5. No abstract available.

PMID:
12170966
33.

Antiretroviral rounds. Time for a holiday.

Piliero PJ, Jenny-Avital E.

AIDS Clin Care. 2000 Mar;12(3):26-7. No abstract available.

PMID:
12170962
34.

Antiretroviral rounds. A co-infection treatment dilemma.

Nunes D, Piliero PJ.

AIDS Clin Care. 2000 Jul;12(7):58-9. No abstract available.

PMID:
12170957
35.

Ritonavir-associated hyperparathyroidism, osteopenia and bone pain.

Piliero PJ, Gianoukakis AG.

AIDS. 2002 Jul 26;16(11):1565-6. No abstract available.

PMID:
12131200
36.

The utility of inhibitory quotients in determining the relative potency of protease inhibitors.

Piliero PJ.

AIDS. 2002 Mar 29;16(5):799-800. No abstract available.

PMID:
11964541
37.

Interaction between ritonavir and statins.

Piliero PJ.

Am J Med. 2002 Apr 15;112(6):510-1. No abstract available.

PMID:
11959074
38.

Resistant to everything.

Mazzullo JM, Piliero PJ.

AIDS Clin Care. 2001 May;13(5):46-7. No abstract available.

PMID:
11682786
39.

Nevirapine-induced hepatitis: a case series and review of the literature.

Piliero PJ, Purdy B.

AIDS Read. 2001 Jul;11(7):379-82. Review.

PMID:
11494710
40.

Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers.

Sadler BM, Piliero PJ, Preston SL, Lloyd PP, Lou Y, Stein DS.

AIDS. 2001 May 25;15(8):1009-18.

PMID:
11399983
41.

Isoniazid-induced beta-hydroxybutyric acidosis.

Piliero PJ, Fish DG.

Ann Intern Med. 2001 May 1;134(9 Pt 1):799. No abstract available.

PMID:
11329248
42.

HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy.

Clifford DB, Yiannoutsos C, Glicksman M, Simpson DM, Singer EJ, Piliero PJ, Marra CM, Francis GS, McArthur JC, Tyler KL, Tselis AC, Hyslop NE.

Neurology. 1999 Feb;52(3):623-5.

PMID:
10025799
43.

Pulmonary zygomycosis after allogeneic bone marrow transplantation.

Piliero PJ, Deresiewicz RL.

South Med J. 1995 Nov;88(11):1149-52.

PMID:
7481989
44.

Acute uveitis associated with rifabutin use in patients with human immunodeficiency virus infection.

Jacobs DS, Piliero PJ, Kuperwaser MG, Smith JA, Harris SD, Flanigan TP, Goldberg JH, Ives DV.

Am J Ophthalmol. 1994 Dec 15;118(6):716-22.

PMID:
7977598
45.

Eastern equine encephalitis presenting as focal neuroradiographic abnormalities: case report and review.

Piliero PJ, Brody J, Zamani A, Deresiewicz RL.

Clin Infect Dis. 1994 Jun;18(6):985-8.

PMID:
8086564

Supplemental Content

Loading ...
Support Center